HERCEPTIN

Opinions on drugs - Posted on Jun 23 2014

Reason for request

Inclusion

Clinical Benefit

Substantial

The actual benefit of subcutaneous (SC) HERCEPTIN is substantial.

Clinical Added Value

no clinical added value

The new subcutaneous formulation of HERCEPTIN is an addition to the range, complementing the intravenous formulation of HERCEPTIN that is currently available.
Consequently, subcutaneous HERCEPTIN does not provide any improvement in actual benefit (level V, non-existent) compared with intravenous HERCEPTIN.